Ocular Therapeutix (NASDAQ: OCUL) — Company Overview, News & Financial Data
Ocular Therapeutix develops innovative eye care products to enhance treatment for various eye disorders.
Ocular Therapeutix
Ocular Therapeutix (NASDAQ:OCUL) focuses on the discovery, development, and commercialization of eye care products designed to treat eye disorders with innovative technologies. This healthcare firm leverages its expertise to create products that offer solutions for conditions like glaucoma, eye infections, and inflammatory diseases. Ocular Therapeutix is committed to enhancing the treatment experience for patients through products that aim to improve efficacy, safety, and compliance. Its projects range from preclinical studies to advanced clinical trials, aiming to address unmet medical needs in ophthalmology and bring about a new era of eye care solutions. The objective is to lead through innovation, making significant contributions to eye health and patient care.
Snapshot
Operations
Products and/or services of Ocular Therapeutix
- Dextenza – A corticosteroid intracanalicular insert for postoperative ocular pain and inflammation.
- OTX-TKI – A bioresorbable hydrogel implant delivering tyrosine kinase inhibitor for wet age-related macular degeneration.
- OTX-TIC – A sustained-release travoprost implant for reducing intraocular pressure in patients with glaucoma or ocular hypertension.
- ReSure Sealant – A hydrogel ocular sealant for wound closure following cataract surgery or corneal transplantation.
- OTX-CSI – A cyclosporine intracanalicular insert for the chronic treatment of dry eye disease.
- OTX-DED – A development project focused on a hydrogel drug delivery platform for dry eye disease.
Ocular Therapeutix executive team
- Pravin U. DugelExecutive Chairman, President & CEO
- Donald Notman Jr.Chief Operating Officer (Leave of Absence)
- Steve MeyersChief Commercial Officer
- Sanjay NayakChief Strategy Officer
- Nadia K. WaheedChief Medical Officer
- Jason RobinsCFO & Principal Accounting Officer
- Peter K. JarrettChief Technical Officer
- Jeffrey S. HeierChief Scientific Officer
- William S. Slattery Jr.Vice President of Investor Relations
- Todd D.C. AndermanChief Legal Officer & Corporate Secretary